This site is intended for US healthcare professionals only.

Image of a man with plaque psoriasis on his arm

Every patient’s plaques are unique,
driven by differences beneath the surface1-3 

It's time to look beyond the plaques

Learn more about the patient experience

Actor portrayal.

PsO is not uniform and manifests differently across patients1,2,4,5

Image of a woman with plaque psoriasis on her arm

Psoriasis can affect patients of all6,7:

  • ages
  • body types
  • skin tones
  • treatment histories

Additionally, plaques can vary in6,7:

  • appearance
  • location
  • presentation
Dive deeper into heterogeneity

Many patients remain dissatisfied despite recent advancements in PsO therapies8

Image of a woman with plaque psoriasis on her neck

1 in 5 patients reported being dissatisfied

or very dissatisfied with their current systemic or topical treatment, according to a 2024 registry study of 1,560 adults with PsO.9

And it goes beyond treatment dissatisfaction. In a study of 386 patients,

7 out of 10 patients reported that PsO impacted their emotional 
well-being.10

Explore the impact of psoriasis

PsO is driven by multiple pathways beyond IL-232,11,12

Beneath the visible differences in PsO lies a complex network of inflammatory signaling.2,11

Discover pathways driving PsO
image

Takeda’s commitment

Takeda brings 245 years of scientific experience to a renewed focus in
dermatology, applying its legacy of innovation towards advancing research and education in PsO.

Through continued collaboration, education, and an ongoing commitment to addressing unmet needs, Takeda aims to help
improve outcomes for people living with psoriatic disease.

Explore our commitment to dermatology

IL=interleukin; PsO=psoriasis.

References

  1. Conrad C, Gilliet M. Psoriasis: from pathogenesis to targeted therapies. Clin Rev Allergy Immunol. 2018;54(1):102-113.
  2. Armstrong AW, Blauvelt A, Callis Duffin K, et al. Psoriasis. Nat Rev Dis Primers. 2025;11(1):45.
  3. Zhang S, Chang M, Zheng L, et al. Deep analysis of skin molecular heterogeneities and their significance on the precise treatment of patients with psoriasis. Front Immunol. 2024;15:1326502.
  4. Singh R, Koppu S, Perche PO, Feldman SR. The cytokine-mediated molecular pathophysiology of psoriasis and its clinical implications. Int J Mol Sci. 2021;22(23):12793.
  5. Swindell WR, Xing X, Stuart PE, et al. Heterogeneity of inflammatory and cytokine networks in chronic plaque psoriasis. PLoS One. 2012;7(3):e34594.
  6. Guo J, Zhang H, Lin W, Lu L, Su J, Chen X. Signaling pathways and targeted therapies for psoriasis. Signal Transduct Target Ther. 2023;8(1):437.
  7. Armstrong AW, Read C. Pathophysiology, clinical presentation, and treatment of psoriasis: a review. JAMA. 2020;323(19):1945-1960.
  8. Merola JF, Ogdie A, Gottlieb AB, et al. Patient and physician perceptions of psoriatic disease in the United States: results from the UPLIFT survey. Dermatol Ther (Heidelb). 2023;13(6):1329-1346.
  9. Song WB, Michaud K, Lonowski SL, et al. The FORWARD psoriasis registry: patient-reported outcomes in a novel psoriasis registry and comparison of traditional, dermatologist-led enrollment with web-based patient enrollment. J Psoriasis Psoriatic Arthritis. 2025;10(2):37-50.
  10. Armstrong A, Levi NA, Schneider B, et al. Patient-identified treatment goals for psoriatic disease: results from a US patient survey. J Psoriasis Psoriatic Arthritis. 2024;10(1):11-21.
  11. Sieminska I, Pieniawska M, Grzywa TM. The immunology of psoriasis—current concepts in pathogenesis. Clin Rev Allergy Immunol. 2024;66(2):164-191.
  12. Cantó E, Del Prado ME, Villarrasa E, et al. Transcriptomic identification of immune-related hubs as candidate predictor biomarkers of therapeutic response in psoriasis. Int J Mol Sci. 2025;26(17):8118.